Genfit
Suletud
SektorTervishoid
11.48 -2.21
Ülevaade
Aktsiahinna muutus
24h
Min
11.36
Max
11.68
Sissetulek | -76M |
|---|---|
Müük | 32M |
Aktsiakasum | -1.525 |
Kasumimarginaal | -237.939 |
Töötajad | 161 |
EBITDA | -7M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +29.76% upside |
Järgmine tulemuste avaldamine | 29. sept 2026 |
|---|
Turukapital | 591M |
|---|---|
Eelmine avamishind | 13.69 |
Eelmine sulgemishind | 11.48 |
Genfit Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Genfit Prognoos
Hinnasiht
By TipRanks
29.76% tõus
12 kuu keskmine prognoos
Keskmine 15 EUR 29.76%
Kõrge 15 EUR
Madal 15 EUR
Põhineb 1 Wall Streeti analüütiku instrumendi Genfit 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Genfit
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.